Literature DB >> 2023522

Cardiovascular characterization of SD-3211, a novel benzothiazine calcium channel blocker, in isolated rabbit hearts.

N Miyawaki1, T Furuta, T Shigei, H Yamauchi, T Iso.   

Abstract

The cardiovascular effects of SD-3211, a novel benzothiazine Ca++ channel blocker, were compared with those of diltiazem and nicardipine in Langendorff-perfused rabbit hearts. SD-3211 was more potent in increasing coronary artery flow than in depressing cardiac function (i.e., contractile force, heart rate and conduction time). The relative specificity of SD-3211 for coronary vasodilation to cardiodepression was clearly greater than that of diltiazem, but less than that of nicardipine. Thus, the present study demonstrates that SD-3211, despite a non-dihydropyridine type of Ca++ channel blocker, can be characterized as a potent coronary vasodilator with a little effect on cardiac function.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2023522     DOI: 10.1016/0024-3205(91)90222-w

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  3 in total

1.  Semotiadil inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.

Authors:  T Takahashi; T Kanda; S Imai; T Suzuki; I Kobayashi; K Murata
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

2.  Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model.

Authors:  T Mori; Y Ishigai; A Fukuzawa; K Chiba; T Shibano
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

3.  Effects of semotiadil fumarate, a novel Ca2+ antagonist, on cytosolic Ca2+ level and force of contraction in porcine coronary arteries.

Authors:  M Kageyama; T Yanagisawa; N Taira
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.